ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002

Its studies are led by Xadcera Biopharmaceutical (Suzhou).

Furthest: phase 2, since Dec 11, 20241 company-led study, 1 open or runningNext primary completion: Oct 8, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xadcera Biopharmaceutical (Suzhou)11 open or runningphase 2since Dec 11, 2024Dec 11, 2024Oct 8, 2027phase 2 · NCT06751329

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2024First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT06751329 · 280 planned · United States, Australia

Ahead

  1. Oct 8, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT06751329

TargetBeta

ERBB3 →MUC1 →read by rule
“An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) human epidermal growth factor receptor 3 (HER3; ErbB3) and mucin-1 (MUC1) ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06751329Ovarian Neoplasms · United States, Australia2RecruitingOct 8, 2027280

How it is read

Names in the registry

  • “DM002”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.